

PubMed

Abstract ▾

Full text links



J Pharmacol Exp Ther. 2015 Mar;352(3):420-8. doi: 10.1124/jpet.114.219303. Epub 2014 Dec 16.

## Curcumin attenuates opioid tolerance and dependence by inhibiting Ca<sup>2+</sup>/calmodulin-dependent protein kinase II $\alpha$ activity.

Hu X<sup>1</sup>, Huang F<sup>1</sup>, Szymusiak M<sup>1</sup>, Liu Y<sup>2</sup>, Wang ZJ<sup>2</sup>.

### Author information

<sup>1</sup>Department of Biopharmaceutical Sciences (X.H., F.H., Y.L., Z.J.W.), Cancer Center (Z.J.W.), and Department of Chemical Engineering (M.S., Y.L.), University of Illinois, Chicago, Illinois.

<sup>2</sup>Department of Biopharmaceutical Sciences (X.H., F.H., Y.L., Z.J.W.), Cancer Center (Z.J.W.), and Department of Chemical Engineering (M.S., Y.L.), University of Illinois, Chicago, Illinois zjwang@uic.edu liuying@uic.edu.

### Abstract

Chronic use of opioid analgesics has been hindered by the development of opioid addiction and tolerance. We have reported that curcumin, a natural flavonoid from the rhizome of *Curcuma longa*, attenuated opioid tolerance, although the underlying mechanism remains unclear. In this study, we tested the hypothesis that curcumin may inhibit Ca(2+)/calmodulin-dependent protein kinase II  $\alpha$  (CaMKII $\alpha$ ), a protein kinase that has been previously proposed to be critical for opioid tolerance and dependence. In this study, we used state-of-the-art polymeric formulation technology to produce poly(lactic-co-glycolic acid) (PLGA)-curcumin nanoparticles (nanocurcumin) to overcome the drug's poor solubility and bioavailability, which has made it extremely difficult for studying in vivo pharmacological actions of curcumin. We found that PLGA-curcumin nanoparticles reduced the dose requirement by 11- to 33-fold. Pretreatment with PLGA-curcumin (by mouth) prevented the development of opioid tolerance and dependence in a dose-dependent manner, with ED50 values of 3.9 and 3.2 mg/kg, respectively. PLGA-curcumin dose-dependently attenuated already-established opioid tolerance (ED50 = 12.6 mg/kg p.o.) and dependence (ED50 = 3.1 mg/kg p.o.). Curcumin or PLGA-curcumin did not produce antinociception by itself or affect morphine (1-10 mg/kg) antinociception. Moreover, we found that the behavioral effects of curcumin on opioid tolerance and dependence correlated with its inhibition of morphine-induced CaMKII $\alpha$  activation in the brain. These results suggest that curcumin may attenuate opioid tolerance and dependence by suppressing CaMKII $\alpha$  activity.

Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

PMID: 25515789 [PubMed - indexed for MEDLINE] PMCID: PMC4352596 [Available on 2016-03-01]



Publication Types, MeSH Terms, Substances, Grant Support ▾

LinkOut - more resources ▾

## PubMed Commons

[PubMed Commons home](#)

 0 comments

[How to join PubMed Commons](#)